Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California
Irvine, CA (PRWEB) July 06, 2015 -- Proove Biosciences, a commercial and research leader in Personalized Medicine, recently hosted their 2015 bi-annual Pain Management Medical Advisory Board meeting in Palm Springs, California. At the bi-annual meeting, the Medical Advisory Board met with Proove Biosciences’ executive Research and Development team to discuss new clinical practice and research ideas. The Board also discussed the development of new medical guidelines for Proove’s proprietary genetic tests and decided on the future direction and ever-evolving improvement of Proove Biosciences.
“We have plans to expand our testing menu to offer 30 plus tests by the end of 2015”, Brian Meshkin, Founder and CEO of Proove Biosciences said. “Due to our consistent record growth, we have found that by gathering these influential and distinguished physicians and researchers and by fostering the discussion of Proove testing, we gain extremely constructive insights into the treatment of pain and the clinical value of our work.”
“Proove testing is the future of medicine in general,” said Dr. Katrina Lewis of The Pain Center in Spokane, Washington. “I am a firm believer in their products, it has helped me make much better decisions for myself and my patients. These products will change patient lives for the better.”
Some others in attendance were Dr. Lynn Webster, immediate past-president of American Academy of Pain Medicine and vice president Scientific Affairs at PRA Health Sciences, Dr. Luda Diatchenko of McGill University, Dr. Standiford Helm, VP of the American Society of Interventional Pain Physicians, Dr. Gregory Smith of GS Medical and Comprehensive Pain Relief Group, and Dr. Steven Richeimer of University of Southern California Pain Center. Dr. Richheimer stated, “The biggest takeaway from this meeting was realizing the potential! This field is going to change the science of pain and the clinical practice of pain management - and Proove is well positioned to be the leader.”
About Proove Biosciences Our Mission is to Change the Future of Medicine. Proove is the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could’ve ever prescribed medications without knowing how a patient would respond. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of personalized pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve outcomes – both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
Nicole McMillan, Proove Biosciences, http://www.proovebio.com, +1 855-776-6832 Ext: 1546, [email protected]
Share this article